Drugs

Adjuvant Capital is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges. It focuses on historically overlooked market segments, leveraging expertise to translate opportunities into social and financial returns. The firm's investment model is heavily influenced by global trends such as climate change and antimicrobial resistance.